이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cyclo Therapeutics 관리

관리 기준 확인 4/4

Cyclo Therapeutics' CEO는 N. Fine, Sep2015 에 임명되었습니다 의 임기는 8.75 년입니다. 총 연간 보상은 $ 672.89K, 80.4% 로 구성됩니다. 80.4% 급여 및 19.6% 보너스(회사 주식 및 옵션 포함). 는 $ 870.25K 가치에 해당하는 회사 주식의 2.6% 직접 소유합니다. 870.25K. 경영진과 이사회의 평균 재임 기간은 각각 6.8 년과 9.6 년입니다.

주요 정보

N. Fine

최고 경영자

US$672.9k

총 보상

CEO 급여 비율	80.4%
CEO 임기	9.1yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	7.2yrs
이사회 평균 재임 기간	9.9yrs

최근 관리 업데이트

Recent updates

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Aug 16

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

Jul 12

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Apr 27

CEO 보상 분석

N. Fine 의 보수는 Cyclo Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$673k	US$541k	-US$20m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$541k	-US$15m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$508k	-US$14m
Sep 30 2021	n/a	n/a	-US$14m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$489k	US$400k	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$8m
Dec 31 2019	US$490k	US$400k	-US$8m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$467k	US$400k	-US$4m
Sep 30 2018	n/a	n/a	-US$4m
Jun 30 2018	n/a	n/a	-US$4m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$441k	US$400k	-US$4m

보상 대 시장: N. 의 총 보상 ($USD 672.89K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: N. 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

N. Fine (67 yo)

9.1yrs

테뉴어

US$672,888

보상

Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...

리더십 팀

이름	위치	테뉴어	보상	소유권
N. Fine	CEO & Director	9.1yrs	US$672.89k	2.59% $ 551.3k
C. Strattan	Founder & Director	no data	US$33.00k	1.06% $ 226.4k
Joshua Fine	CFO & Secretary	10.8yrs	US$463.98k	0.059% $ 12.5k
Michael Lisjak	Senior VP of Business Development & Chief Regulatory Officer	5.3yrs	US$473.21k	0.043% $ 9.2k
Jeffrey Tate	COO, Chief Quality Officer & Director	9.1yrs	US$255.14k	0.32% $ 68.2k
Lori McKenna	Global Head of Patient Advocacy	3.4yrs	데이터 없음	데이터 없음
Karen Mullen	Interim Chief Medical Officer	1.8yrs	데이터 없음	데이터 없음

7.2yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: CYTH 의 관리팀은 노련하고 경험 (평균 재직 기간 6.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
N. Fine	CEO & Director	10.7yrs	US$672.89k	2.59% $ 551.3k
C. Strattan	Founder & Director	34.8yrs	US$33.00k	1.06% $ 226.4k
Jeffrey Tate	COO, Chief Quality Officer & Director	14.2yrs	US$255.14k	0.32% $ 68.2k
William Shanahan	Independent Director	8.3yrs	US$40.13k	0.47% $ 99.1k
Markus Sieger	Independent Chairman	10.7yrs	US$66.38k	1.21% $ 257.3k
Rita Colwell	Co-Chair of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Sharon Hrynkow	Co-Chairman of Scientific Advisory Board	9.9yrs	US$600.09k	데이터 없음
F. Ostronic	Independent Vice Chairman	10.5yrs	US$41.25k	1.22% $ 258.5k
Caroline Hastings	Member of Scientific Advisory Board	9.6yrs	데이터 없음	데이터 없음
Benny Liu	Member of Scientific Advisory Board	9.4yrs	데이터 없음	데이터 없음
Gerald F. Cox	Member of Scientific Advisory Board	3.1yrs	데이터 없음	데이터 없음
Randall Toig	Independent Director	6.6yrs	US$35.63k	0.44% $ 93.2k

9.9yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: CYTH 의 이사회는 경험(평균 재직 기간 9.6 년)으로 간주됩니다.

Cyclo Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

CEO & Director exercised options to buy US$293k worth of stock.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Recent updates

Insufficient new directors

Cyclo Therapeutics, Inc. announced that it has received $3 million in funding from Rafael Holdings, Inc.

Rafael Holdings, Inc. (NYSE:RFL) entered into a definitive agreement to acquire unknown remaining stake of Cyclo Therapeutics, Inc. (NasdaqCM:CYTH).

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1

Consensus EPS estimates fall by 12%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) completed the acquisition of Applied Molecular Transport Inc. (NasdaqCM:AMTI) from a group of shareholders for $10.2 million.

Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

CEO & Director exercised options to buy US$293k worth of stock.

Consensus revenue estimates decrease by 29%, EPS upgraded

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) entered into a definitive agreement to acquire Applied Molecular Transport Inc. (NasdaqCM:AMTI) for $11.9 million.

Cyclo Therapeutics, Inc. Appoints Vivien Wong as Member of the Board

New major risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. announced that it has received $5 million in funding from Rafael Holdings, Inc.

Cyclo Therapeutics, Inc., Annual General Meeting, Jul 31, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Appoints William Conkling to Serve as Director

CEO & Director recently bought US$213k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Cyclo Therapeutics, Inc. Provides Clinical Program Update

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc. Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2B Study of Trappsol Cyclo for the Treatment of Early Alzheimer’S Disease

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M

Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cyclo Therapeutics, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$10.00

Consensus revenue estimates increase by 16%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclo Therapeutics to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics, Inc. Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Independent Vice Chairman recently bought US$53k worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 3Q 2020)

Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$1.60 loss in 2Q 2020)

Consensus forecasts updated

Cyclo Therapeutics, Inc. Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics Provides Update on Trappsol® Cyclo

Cyclo therapeutics to join Russell 2000 Index

We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate

Cyclo Therapeutics Provides Business Update

First quarter 2021 earnings released: US$0.76 loss per share (vs US$2.18 loss in 1Q 2020)

Cyclo Therapeutics, Inc. Announces Design of Pivotal Phase 3 Study Evaluating Trappsol Cyclo in Niemann-Pick Type C1

Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo

Independent Chairman recently bought US$81k worth of stock

Full year 2020 earnings released: US$5.59 loss per share (vs US$6.96 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Cyclo Therapeutics, Inc. Appoints Russ Belden as Acting Chief Commercial Officer

Cyclo Therapeutics, Inc. Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on Agreement of Paediatric Investigation Plan for Trappsol® Cyclo™

Cyclo Therapeutics, Inc. Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

CEO 보상 분석